首页 工具
登录
购物车
Derazantinib

Derazantinib

产品编号 TQ0228   CAS 1234356-69-4
别名: ARQ-087

Derazantinib (ARQ-087) 是一种有效的,ATP 竞争型的,具有口服活性的酪氨酸激酶抑制剂,能够抑制软骨细胞FGFR1 (IC50:4.5 nM)、FGFR2 (IC50:1.8 nM)、FGFR3 (IC50:4.35nM)。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
Derazantinib Chemical Structure
Derazantinib, CAS 1234356-69-4
规格 价格/CNY 货期 数量
1 mg ¥ 656 现货
2 mg ¥ 955 现货
5 mg ¥ 1,570 现货
10 mg ¥ 2,890 现货
25 mg ¥ 4,850 现货
50 mg ¥ 6,890 现货
100 mg ¥ 9,330 现货
1 mL * 10 mM (in DMSO) ¥ 1,630 现货
其他形式的 Derazantinib:
产品目录号及名称: Derazantinib (TQ0228)
点击图片重新获取验证码
选择批次  
纯度: 99.95%
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 Derazantinib (ARQ-087) (ARQ-087) is an ATP competitive tyrosine kinase inhibitor. It exhibits potent activity against FGFR1/FGFR2/FGFR3 chondrocytes (IC50s: 4.5 nM/1.8 nM/4.5 nM).
靶点活性 FGFR2:1.8 nM, FGFR1:4.5 nM, FGFR3:4.5 nM
体外活性 In cells, inhibition of FGFR2 auto-phosphorylation and other proteins downstream in the FGFR pathway (FRS2α, AKT, ERK) is evident by the response to Derazantinib treatment. Derazantinib has anti-proliferative activity in cell lines driven by FGFR dysregulation, including amplifications, fusions, and mutations. Cell cycle studies in cell lines with high levels of FGFR2 protein show a positive relationship between Derazantinib induced G1 cell cycle arrest and subsequent induction of apoptosis [1]. Derazantinib rescues the FGF2-mediated growth arrest with EC50 at about 100 nM, with no significant toxicity detected for up to 500 nM. The concentration range at which Derazantinib significantly suppresses the FGF2 effect is between 70-500 nM. Derazantinib inhibits FGF-mediated loss of extracellular matrix and induction of chondrocyte premature senescence. Derazantinib rescues FGF-mediated inhibition of chondrocyte differentiation in tibia cultures. Derazantinib inhibits FGFR1-4 but no other receptor tyrosine kinases in the cell-free kinase assay. Derazantinib inhibits FGFR1 and FGFR2 mutants associated with craniosynostoses [2].
体内活性 Derazantinib is effective at inhibiting tumor growth in FGFR2 altered, SNU-16 and NCI-H716, xenograft tumor models with gene amplification and fusions [1]. Most of the embryos exhibit abnormal external phenotype (81.3%) in Derazantinib-injected wings, possibly due to inhibition of proliferation of limb bud mesenchyme [2].
激酶实验 Derazantinib is titrated in DMSO utilizing a 3-fold dilution scheme and then diluted 10-fold further in deionized water for a final DMSO concentration of 10%. A volume (2.5 μL) of these dilutions or vehicle is added to each well of a reaction plate. FGFR1 or FGFR2 is added to assay buffer to each well in a volume of 17.5 μL for a final concentration of 0.50 or 0.25 nM, respectively. After a 30-minute pre-incubation period, ATP and substrate are added in assay buffer (5 μL) for final concentrations of 0-1,000 μM ATP and 80 nM biotinylated-PYK2, for a final reaction volume of 25 μL. The plates are incubated for 60 minutes at room temperature and then stopped in the dark by the addition of 10 μL stop/detection mixture prepared in assay buffer containing EDTA [1].
细胞实验 Cells are seeded at 3000-5000 cells per well with 130 μL media in 96-well tissue culture-treated plates. The cells are incubated overnight and subsequently treated with 3-fold serial dilutions of Derazantinib starting at 100 μM. The cells are returned to a 37°C humidified incubator for 72 hours. Cell proliferation is measured using the MTS assay [1].
动物实验 Female NCr nu/nu mice (SNU-16) or CB17 SCID mice (NCI-H716) with well established (400 mg) subcutaneous tumors are given a single oral dose of Derazantinib or vehicle control. Plasma and tumor samples are collected 4 hours post single dose. Derazantinib is administered orally. The dosing volume for all groups is 10 mL/kg or 0.1 mL/10 g body weight [1].
别名 ARQ-087
分子量 468.57
分子式 C29H29FN4O
CAS No. 1234356-69-4

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 98 mg/mL (209.15 mM)

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1342 mL 10.6708 mL 21.3415 mL 53.3538 mL
5 mM 0.4268 mL 2.1342 mL 4.2683 mL 10.6708 mL
10 mM 0.2134 mL 1.0671 mL 2.1342 mL 5.3354 mL
20 mM 0.1067 mL 0.5335 mL 1.0671 mL 2.6677 mL
50 mM 0.0427 mL 0.2134 mL 0.4268 mL 1.0671 mL
100 mM 0.0213 mL 0.1067 mL 0.2134 mL 0.5335 mL

计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

参考文献

1. Hall TG, et al. Preclinical Activity of ARQ-087, a Novel Inhibitor Targeting FGFR Dysregulation. PLoS One. 2016 Sep 14;11(9):e0162594. 2. Balek L, et al. ARQ-087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3. Bone. 2017 Dec;105:57-66.
ENMD-2076 EGFR-IN-16 KHS101 hydrochloride FGFR4-IN-1 EOC317 ODM-203 Nintedanib Tyrosine kinase-IN-1

相关化合物库

该产品包含在如下化合物库中:
抗癌活性化合物库 抗癌药物库 酪氨酸激酶分子库 抗癌临床化合物库 抗肝癌化合物库 ReFRAME 相关化合物库 细胞重编程化合物库 抗癌化合物库 抗纤维化化合物库 已知活性化合物库

剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Derazantinib 1234356-69-4 Angiogenesis Tyrosine Kinase/Adaptors FGFR ARQ-087 ARQ087 Fibroblast growth factor receptor inhibit ARQ 087 Inhibitor inhibitor

 

陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼